氯喹和羟氯喹治疗干眼症
Chloroquine and Hydroxychloroquine in the Treatment of Dry Eye Disease.
作者信息
Prinz Julia, Maffulli Nicola, Fuest Matthias, Walter Peter, Hildebrand Frank, Migliorini Filippo
机构信息
RWTH University Hospital of Aachen, Pauwelsstraße 30, 52074 Aachen, Germany.
Department of Medicine, Surgery and Dentistry, University of Salerno, 84081 Fisciano, Italy.
出版信息
Diseases. 2023 Jun 12;11(2):85. doi: 10.3390/diseases11020085.
The role of chloroquine (CQ) and hydroxychloroquine (HCQ) in the management of dry eye disease is still unclear. This systematic review and meta-analysis investigates the efficacy and feasibility of CQ and HCQ in patients with dry eye disease. In February 2023, PubMed, Embase, Google Scholar, and Web of Science were accessed. Data from 462 patients (mean age 54.4 ± 2.8 years) were collected. Compared to baseline, the tear breakup time ( < 0.0001) and Schirmer I test ( < 0.0001) were significantly increased, and the Ocular Surface Disease Index (OSDI, < 0.0001) and corneal staining ( < 0.0001) were significantly decreased at the last follow-up in the CQ/HCQ group. At the last follow-up, the OSDI was significantly lower in the CQ/HCQ group compared to the control group ( < 0.0001). Corneal staining was significantly greater in the control group compared to the CQ/HCQ group ( < 0.0001). The Schirmer I test showed no significant difference between the groups ( = 0.2). Altogether, CQ and HCQ improved the symptoms and signs of dry eye disease.
氯喹（CQ）和羟氯喹（HCQ）在干眼病治疗中的作用仍不明确。本系统评价和荟萃分析旨在研究CQ和HCQ对干眼病患者的疗效和可行性。2023年2月，检索了PubMed、Embase、谷歌学术和科学网。收集了462例患者（平均年龄54.4±2.8岁）的数据。与基线相比，CQ/HCQ组在最后一次随访时泪膜破裂时间（<0.0001）和泪液分泌试验I（<0.0001）显著增加，眼表疾病指数（OSDI，<0.0001）和角膜染色（<0.0001）显著降低。在最后一次随访时，CQ/HCQ组的OSDI显著低于对照组（<0.0001）。对照组的角膜染色显著高于CQ/HCQ组（<0.0001）。泪液分泌试验I显示两组之间无显著差异（=0.2）。总之，CQ和HCQ改善了干眼病的症状和体征。
Zotero 插件